IL189599A0 - Methods to enhance chemotherapy - Google Patents

Methods to enhance chemotherapy

Info

Publication number
IL189599A0
IL189599A0 IL189599A IL18959908A IL189599A0 IL 189599 A0 IL189599 A0 IL 189599A0 IL 189599 A IL189599 A IL 189599A IL 18959908 A IL18959908 A IL 18959908A IL 189599 A0 IL189599 A0 IL 189599A0
Authority
IL
Israel
Prior art keywords
methods
enhance chemotherapy
chemotherapy
enhance
Prior art date
Application number
IL189599A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37758501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL189599(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL189599A0 publication Critical patent/IL189599A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL189599A 2005-08-19 2008-02-18 Methods to enhance chemotherapy IL189599A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70997805P 2005-08-19 2005-08-19
US73473605P 2005-11-08 2005-11-08
PCT/US2006/032668 WO2007022523A2 (en) 2005-08-19 2006-08-21 Methods to enhance chemotherapy

Publications (1)

Publication Number Publication Date
IL189599A0 true IL189599A0 (en) 2008-08-07

Family

ID=37758501

Family Applications (1)

Application Number Title Priority Date Filing Date
IL189599A IL189599A0 (en) 2005-08-19 2008-02-18 Methods to enhance chemotherapy

Country Status (9)

Country Link
US (1) US20070043012A1 (https=)
EP (1) EP1951046B1 (https=)
JP (3) JP2009504788A (https=)
CN (1) CN101365336B (https=)
AU (1) AU2006280945A1 (https=)
BR (1) BRPI0615180A2 (https=)
CA (1) CA2619828A1 (https=)
IL (1) IL189599A0 (https=)
WO (1) WO2007022523A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) * 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
EP2978439B1 (en) 2013-03-24 2017-08-16 Biokine Therapeutics Ltd. A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
EP3125919A4 (en) * 2014-02-19 2018-01-03 Microconstants China Inc. Chemokine receptor antagonist and its combinational therapy
KR101759688B1 (ko) * 2015-01-16 2017-07-20 서울대학교산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
WO2016114634A2 (ko) * 2015-01-16 2016-07-21 서울대학교 산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
EP3288638A1 (en) * 2015-04-25 2018-03-07 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN108348545A (zh) * 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的t细胞及其用途
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
TWI781469B (zh) * 2020-10-27 2022-10-21 行政院原子能委員會核能研究所 複合物、造影劑及治療與cxcr4接受體相關疾病的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
DE60042030D1 (de) 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1361851B1 (en) 2001-01-23 2007-02-21 P & G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP2006524242A (ja) * 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
US20040202935A1 (en) 2003-04-08 2004-10-14 Jeremy Barker Cathode active material with increased alkali/metal content and method of making same
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.

Also Published As

Publication number Publication date
WO2007022523A3 (en) 2007-11-22
EP1951046B1 (en) 2012-07-18
BRPI0615180A2 (pt) 2011-05-03
US20070043012A1 (en) 2007-02-22
CA2619828A1 (en) 2007-02-22
JP2013231086A (ja) 2013-11-14
JP2009504788A (ja) 2009-02-05
CN101365336B (zh) 2013-05-29
AU2006280945A1 (en) 2007-02-22
WO2007022523A2 (en) 2007-02-22
CN101365336A (zh) 2009-02-11
EP1951046A4 (en) 2010-03-17
JP2013107903A (ja) 2013-06-06
EP1951046A2 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
IL189599A0 (en) Methods to enhance chemotherapy
PT1850873T (pt) Anticorpos contra tgfbeta
GB2422141B (en) Improvements relating to construction
GB2443778B (en) Improvements relating to lighting
GB0525957D0 (en) Methods
EP1889173A4 (en) SUBSCRIPTION OF CONTENT
EP2115136A4 (en) NOVEL PROCEDURE
GB0715741D0 (en) Methods
GB0600299D0 (en) Way to go
GB0518425D0 (en) Methods
GB0607377D0 (en) Novel Methods
GB0516204D0 (en) Methods
GB0514661D0 (en) Methods
GB2438812B (en) Improvements to cabling
HK1120999A (en) Methods to enhance chemotherapy
GB0526212D0 (en) Methods
GB0517718D0 (en) Further improvement to brikmat
GB0500847D0 (en) Claims to be made
GB2423802B (en) Improvements relating to vacuum-brake-boosters
GB0507990D0 (en) Improvements relating to lantibiotics
GB0519269D0 (en) Improvements to cabling
GB0413163D0 (en) Improvements to signware
GB0508694D0 (en) Novel methods
GB0506245D0 (en) Improvements to collar
GB0518828D0 (en) Improvements to munitions